Thrombotic and ischemic event reporting with anticoagulant reversal agents: a multi-agent FAERS pharmacovigilance study.

AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) - Daiichi Sankyo, AstraZeneca

Praxbind (idarucizumab) - Boehringer Ingelheim

http://www.ncbi.nlm.nih.gov/pubmed/42749984

Ertugrul Okuyan; Esra Danisman; Hasan Burak Isleyen; Mahmut Uluganyan; Nusret Acikgoz; Oguzhan Abanoz; Ramazan Ozdemir; Sercan Bulut; Sevil Tugrul Yavuz

Sep 17, 2026